After zipping into the accelerated approval of its experimental mRNA gene therapy for COVID, Moderna is hoping for the same swift and accelerated approval for its mRNA cancer vaccine, Moderna president Steven Hoge announced at an annual health care conference March 13, 2023.
Hoge said he’s banking on both Merck’s and Moderna’s mRNA-4157 cancer vaccine trial data to get them the accelerated green light. The process targets stage III/IV melanoma patients with high risk of recurrence following complete resection (surgical removal).
As the research progresses, the company will be looking at, “whether translational and biomarker data will ultimately show a selection of patients that respond even more strongly to the treatment leading to a higher benefit and improved hazard ratio,” he said.
SOURCE:
Genetic Engineering & Biotechnology News March 13, 2013
Source: Original Article
Publish Date: 2023-03-13 19:05:48